Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final “common arm”: Comparative outcomes analysis of JCOG 9511 and SWOG 0124

Primo Lara,Kari Chansky,Taro Shibata,Haruhiko Fukuda,Tomohide Tamura,Nagahiro Saijo,Mary W. Redman,H. J. Lenz,Ronald B. Natale,David R. Gandara

Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final “common arm”: Comparative outcomes analysis of JCOG 9511 and SWOG 0124

2016

Primo Lara
Kari Chansky
Taro Shibata
Haruhiko Fukuda
Tomohide Tamura
Nagahiro Saijo
Mary W. Redman
H. J. Lenz
Ronald B. Natale
David R. Gandara

8027 Background: S0124 was a large North American phase III trial (n=651) that failed to confirm a survival benefit for cisplatin/irinotecan over cisplatin/etoposide in patients with E-SCLC, contra...

Keywords:

Irinotecan
Etoposide
Cisplatin/irinotecan
Pathology
Oncology
Cisplatin
Cisplatin/etoposide
Extensive-stage small cell lung cancer
Internal medicine
Medicine
in patient
outcomes analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations